RENBIO

WIPO WIPO 2021

Schützen Sie diese Marke vor Nachahmern!

Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.

Die Internationale Marke RENBIO wurde als Wortmarke am 29.04.2021 bei der Weltorganisation für geistiges Eigentum angemeldet.

Markendetails Letztes Update: 15. November 2022

Markenform Wortmarke
Aktenzeichen 1599800
Länder Australien Brasilien Kanada China Europäische Gemeinschaft Großbritannien Indien Japan
Basismarke US Nr. 90309237, 10. November 2020
Anmeldedatum 29. April 2021
Ablaufdatum 29. April 2031

Markeninhaber

30-02 48th Avenue
Long Island City NY 11101
US

Markenvertreter

Morgan, Lewis & Bockius LLP, One Federal Street US

Waren und Dienstleistungen

01 Biological products, namely, DNA circle, DNA primers, linear DNA and buffers for use in research and development of pharmaceuticals and for manufacture of pharmaceuticals; biological products, namely, antibodies, multi-specific antibodies, antibody fragments, proteins, chimeric proteins, drug conjugates and enzymes, for use in research and development of pharmaceuticals and for manufacture of pharmaceuticals
05 Chemical preparations for gene delivery pharmaceuticals for treating genetic disorders, and for use as medical and veterinary diagnostic reagents for therapeutic analysis; biochemical preparations for medical and veterinary purposes, namely, biochemical preparations for gene therapy, for treating genetic disorders, and for use as medical and veterinary diagnostic reagents for gene therapy analysis; gene therapy and prophylactic products, namely, gene delivery pharmaceuticals for the treatment of genetic or cell based conditions; pharmaceutical preparations containing nucleic acid sequences that encode monoclonal antibodies for the treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; pharmaceutical compositions for the prevention and treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; biological preparations for the treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; nucleic acid sequences for medical purposes; pharmaceutical compositions, namely, a nucleotide sequence that encodes an antigen, such as a DNA plasmid having an antigen encoding sequence and like DNA, for the prevention and treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; pharmaceutical preparations for human use for the treatment and prevention of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; pharmaceutical preparations for human and veterinary use, namely, antibiotics, antifungals and anti-virals
10 Medical apparatus for the administration of biopharmaceuticals and vaccines, namely, drug delivery devices and systems; medical devices, namely, for electroporation mediated administration of drugs to humans and animals; delivery systems for administration of biopharmaceuticals and vaccines for the preventive or treatment of disease in humans and animals; handheld medical systems and devices using electroporation for the prevention or treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders in humans and animals; handheld clinical delivery systems and devices for the application of electrical fields in tissue, in particular muscle and skin, in conjunction with the administration of biopharmaceuticals
42 Medical and scientific research in the field of drug delivery devices; research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen

Markenhistorie

Datum Belegnummer Bereich Eintrag
10. November 2022 2022/46 Gaz JP RAW: Rule 18ter(2)(ii) GP following a provisional refusal
05. Oktober 2022 2022/40 Gaz CA Ablehnung
02. August 2022 2022/31 Gaz BR Ablehnung
26. Mai 2022 2022/22 Gaz JP Ablehnung
18. Januar 2022 2022/7 Gaz AU RAW: Rule 18ter(2)(ii) GP following a provisional refusal
02. Dezember 2021 2021/52 Gaz CN Ablehnung
01. Dezember 2021 2021/48 Gaz GB Ablehnung
23. November 2021 2021/47 Gaz EM Ablehnung
14. Juli 2021 2021/29 Gaz AU Ablehnung
13. Juli 2021 2021/29 Gaz IN Ablehnung
29. April 2021 2021/24 Gaz US Eintragung

ID: 141599800